1,630 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by First County Bank CT

First County Bank CT acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,630 shares of the company’s stock, valued at approximately $318,000.

Other hedge funds have also modified their holdings of the company. Cetera Investment Advisers grew its holdings in shares of Zoetis by 275.2% during the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock worth $16,259,000 after buying an additional 70,476 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Zoetis during the third quarter valued at approximately $11,684,000. Soltis Investment Advisors LLC acquired a new position in Zoetis during the first quarter valued at approximately $688,000. Bank Pictet & Cie Asia Ltd. lifted its position in shares of Zoetis by 41.0% in the second quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock valued at $6,501,000 after buying an additional 10,900 shares during the last quarter. Finally, Swedbank AB lifted its position in shares of Zoetis by 56.2% in the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock valued at $337,407,000 after buying an additional 700,398 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Up 0.2 %

NYSE ZTS opened at $176.98 on Friday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market cap of $79.85 billion, a price-to-earnings ratio of 33.27, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The business’s fifty day moving average is $185.62 and its 200 day moving average is $180.53.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.36 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is presently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.